An antibody-based molecular switch for continuous small-molecule biosensing.
AuthorsSoh HT
JournalScience advances
PubMed ID37738337
Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement.
AuthorsLiu Y
JournalNature communications
PubMed ID35879297
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
AuthorsAzzariti A
JournalMolecular cancer
PubMed ID35042524
Oligonucleotide conjugated antibody strategies for cyclic immunostaining.
AuthorsGibbs SL
JournalScientific reports
PubMed ID34903759
Synthesis and In Vivo Evaluation of a Site-specifically Labeled Radioimmunoconjugate for Dual-Modal (PET/NIRF) Imaging of MT1-MMP in Sarcomas.
AuthorsKnight JC
JournalBioconjugate chemistry
PubMed ID35867034
Fluorescent Imaging for
AuthorsMcMahon NP, Solanki A, Jones J, Kwon S, Chang YH, Chin K, Nederlof MA, Gray JW, Gibbs SL
JournalProc SPIE Int Soc Opt Eng
PubMed ID32296256
'Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by significant tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and cross talk between signaling pathways. Advances in molecular characterization technologies such as next generation sequencing have helped unravel this ... More
Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides.
AuthorsMcMahon N, Jones J, Eng J, Kwon S, Chang YH, Thibault G, Chin K, Nederlof M, Gray J, Gibbs SL
JournalProc SPIE Int Soc Opt Eng
PubMed ID32280155
Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by significant tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and cross talk between signaling pathways. Advances in molecular characterization technologies such as next generation sequencing have helped unravel this ... More
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.
AuthorsJochems C, Tritsch SR, Knudson KM, Gameiro SR, Rumfield CS, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J
JournalOncoimmunology
PubMed ID30713787
Here we describe a novel bifunctional fusion protein, designated N-809. This molecule comprises the IL-15/IL15Ra superagonist complex containing the Fc-domain of IgG1 (N-803, formerly designated as ALT-803) fused to two single chain anti-PD-L1 domains. The fully human IgG1 portion of the N-809 molecule was designed to potentially mediate antibody dependent ... More